Reata Pharmaceuticals Probability of Future Stock Price Finishing Over 172.36
| RETADelisted Stock | USD 172.36 0.02 0.01% |
Reata |
Reata Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Reata Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Reata Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Reata Pharmaceuticals is not yet fully synchronised with the market data | |
| Reata Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.22 M. Net Loss for the year was (311.9 M) with loss before overhead, payroll, taxes, and interest of (167.63 M). | |
| Reata Pharmaceuticals currently holds about 481.47 M in cash with (204.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.19. | |
| Over 88.0% of the company shares are owned by institutional investors |
Reata Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Reata Stock often depends not only on the future outlook of the current and potential Reata Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Reata Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 36.3 M | |
| Cash And Short Term Investments | 387.5 M |
Reata Pharmaceuticals Technical Analysis
Reata Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Reata Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Reata Pharmaceuticals. In general, you should focus on analyzing Reata Stock price patterns and their correlations with different microeconomic environments and drivers.
Reata Pharmaceuticals Predictive Forecast Models
Reata Pharmaceuticals' time-series forecasting models is one of many Reata Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Reata Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Reata Pharmaceuticals
Checking the ongoing alerts about Reata Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Reata Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Reata Pharmaceuticals is not yet fully synchronised with the market data | |
| Reata Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.22 M. Net Loss for the year was (311.9 M) with loss before overhead, payroll, taxes, and interest of (167.63 M). | |
| Reata Pharmaceuticals currently holds about 481.47 M in cash with (204.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.19. | |
| Over 88.0% of the company shares are owned by institutional investors |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |